Search clinical trials for: FYU-981 Low dose, (Oral daily dosing for 8 weeks)

Total 17 results

Fuji Yakuhin Co., Ltd.

Completed

Study of FYU-981 in Hyperuricemia With or Without Gout

Hyperuricemia

Japan
Fuji Yakuhin Co., Ltd.

Completed

Repeated Dose Phase I Study of FYU-981

Healthy

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.
Fuji Yakuhin Co., Ltd.

Completed

Effect of Topiroxostat on Urinary Albumin Excretion Early Stage Diabetic Nephropathy and Hyperuricemia With or Without Gout (UPWARD)

Diabetic Nephropathy

Japan
Henry Ford Health System

Terminated

Will Hydroxychloroquine Impede or Prevent COVID-19 (WHIP COVID-19)

Coronavirus Infections | COVID-19 | SARS-CoV 2 | Coronavirus

United States
Fox Chase Cancer Center

Withdrawn

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Non-Small Cell Lung Cancer

United States
Region Skane

Withdrawn

Diclofenac add-on to Treatment as Usual for Suicidal Patients

Depression Suicidal

Sweden
University of California, San Francisco
Sandler Family Supporting Foundation

Completed

Effect of an Inhaled Corticosteroid on Airway Gene Expression in Asthma

Asthma

United States
Mediterranea Medica S. L.

Terminated

Mifepristone to Treat Uterine Fibroids

Uterine Fibroids

Cuba
Pfizer

Completed

Study to Assess Pharmacokinetics, Safety and Tolerability of PF-04965842 in Chinese Healthy Participants

HEALTHY

China
Memorial Sloan Kettering Cancer Center
Tufts Medical Center; Lahey Clinic

Completed

Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

Multiple Myeloma

United States
Helsinn Healthcare SA

Active, not recruiting

Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (CINV)

Chemotherapy-induced Nausea and Vomiting

Spain, Germany, Switzerland, China, Czechia, United Kingdom, Greece
Academisch Medisch Centrum - Universiteit van Amsterdam...
Celltrion

Recruiting

inDuctIon tREatment With subCuTaneous Infliximab for Crohn's Disease (DIRECTCD)

Bowel Disease | Inflammatory Disease | Disease Crohn

Netherlands
Sun Yat-sen University

Recruiting

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma

Neuroblastoma

United States
Memorial Sloan Kettering Cancer Center

Completed

Rituximab, Methotrexate, Procarbazine and Vincristine Followed by High-dose Chemotherapy With Autologous Stem-cell Rescue in Newly-diagnosed Primary CNS Lymphoma (PCNSL)

Non-Hodgkin's Lymphoma | CNS Lymphoma | CNS Brain Cancer

United States
Lundquist Institute for Biomedical Innovation at...
Abbott Nutrition; DaVita Dialysis

Completed

Anit-Inflammatory and Anti-Oxidative Nutrition in Dialysis Patients (AIONID)

Inflammation | Oxidative Stress | Hypoalbuminemia | Protein-energy Malnutrition | Chronic Kidney Disease (CKD) Hemodialysis

United States
OHSU Knight Cancer Institute
Oregon Health and Science University

Terminated

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Primary Myelofibrosis | Anemia | Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Anatomic Stage IV Breast Cancer AJCC v8 | Recurrent Acute Myeloid Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic... and other conditions

United States

Search clinical trials for: FYU-981 Low dose, (Oral daily dosing for 8 weeks)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Serbia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations